A Prospective Study of Pulmonary Function in Patients Receiving Mitomycin

摘要: Mitomycin is a chemotherapeutic agent that used to treat variety of solid tumors. Pulmonary toxic reactions from this can be life threatening. We prospectively investigated the utility pulmonary function tests (PFTs) in monitoring for occurrence toxicity due mitomycin. PFTs were obtained at baseline and after three cycles mitomycin therapy. analyzed clinical course, radiologic studies, PFT results 133 patients with metastatic squamous cell carcinoma lung randomized treatment either mitomycin, vinblastine, cisplatin or alone as part prospective protocol North Central Cancer Treatment Group (NCCTG). The diffusing capacity (Dco) was available only 40 third cycle high rate progression death their underlying disease. After chemotherapy, there an average decline Dco 14% (p 20% change correcting hemoglobin) noted 11 (28%). This not associated worse prognosis (p=0.77). Seven (5%) developed severe attributed chemo-therapy, including noncardiogenic edema, interstitial pneumonitis, pleural effusions. Corticosteroid therapy resulted temporary subjective improvement patients. did correlate development these seven In conclusion, (1) incidence clinically significant relatively low (5%), (2) greater than approximately one-fourth receiving (3) use serial shown predictive toxicity.